Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

Marla has worked in the healthcare industry since 2000, starting as a bench chemist with Pfizer in manufacturing. In 2006, ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...